ArticleTranslational gastroenterology and hepatology2026
Prognostic value of IκB kinase-interacting protein (IKBIP) in stomach adenocarcinoma.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stomach adenocarcinoma (STAD) remains a leading cause of cancer-related mortality worldwide, with frequent late-stage diagnosis necessitating the identification of reliable biomarkers. IκB kinase-interacting protein (IKBIP) has been implicated in tumor aggressiveness in other malignancies, but its role in STAD remains poorly understood. This study aimed to investigate the oncogenic role and prognostic value of IKBIP in STAD. Methods: We systematically evaluated IKBIP expression and its clinical significance using data from The Cancer Genome Atlas (TCGA)-STAD, TIMER 2.0, Gene Expression Omnibus (GEO) cohorts (GSE15459, GSE15460, GSE34942), and Kaplan-Meier plotter. Immunohistochemistry was performed on 45 STAD patients to validate protein expression and macrophage infiltration. Stable IKBIP knockdown and overexpression cell lines (SGC7901 and MGC803) were generated to assess proliferation [Cell Counting Kit-8 (CCK-8)], migration, and invasion (Transwell). Quantitative real-time polymerase chain reaction (qRT-PCR) examined epithelial-to-mesenchymal transition (EMT) markers (E-cadherin, N-cadherin, Snail, matrix metalloproteinase 9 (MMP9) and NF-κB pathway genes (p65, IL-6, TNF-α). Correlation analyses evaluated upstream regulators, immune checkpoints, chemoresistance genes, and immune checkpoint blockade (ICB) response prediction via Tumor Immune Dysfunction and Exclusion (TIDE) scores. Results: IKBIP was significantly upregulated in STAD tissues versus normal controls at both mRNA and protein levels. High IKBIP expression correlated with age ≥65 years, advanced tumor (T) stage, higher grade, and independently predicted poor overall survival in both TCGA and institutional cohorts (P<0.05). IKBIP positively correlated with macrophage infiltration, particularly M2-polarized (CD163 Conclusions: IKBIP may function as a novel oncogenic driver in STAD through dual mechanisms-remodeling the immune microenvironment via M2 macrophage polarization and immune checkpoint modulation, and promoting EMT and NF-κB signaling to enhance tumor invasion and metastasis. These findings position IKBIP as a potential prognostic biomarker and a potential therapeutic target, with utility in predicting ICB response and chemotherapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.